Saturday 17 October 2026 Export COGT’s income statement to Excel — free account

Cogent Biosciences, Inc.

In the quarter to June 2026, EPS grew 1.89% and free cash flow fell 42.0%, each against the same quarter a year earlier.

29.52 0.01 +0.03%

Follow COGT

Alert me

Market cap: $5.1B
P/E: 0.0×
Fwd P/E: −5.2×
Dividend yield: —
F-score: 3/9
Altman Z: 3.55
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 383.89

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	4	1	—	1	—	—	—	—	1	—	—

Insider Ownership 8.87%

Capital & Financial Ratios $m

Market Cap 5,120.00

Revenue 23.16

Net Income (377.18)

Free Cash Flow (309.24)

Net Debt (568.84)

Current Ratio 13.57

Debt/Equity 0.42

P/E ratio 0.00

Fwd P/E (5.21)

P/S ratio 217.97

P/B ratio 10.79

Past 5Y EPS Growth —

This Y EPS Growth (2.51%)

Next Y EPS Growth 51.40%

Next Y revenue growth 0.62%

Next 5Y EPS Growth 36.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 92.23%

10-year low 10-year high

P/B against its own 10 years 89.36%

10-year low 10-year high

EV/Sales against its own 10 years 91.68%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	266	287	901	792
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	271	296	910	805

	2023	2024	2025	Q'26
Payables	11	12	10	7
ST’ Debt	—	—	—	—
Other	—	—	—	—
	38	56	64	59

Compound Annual Growth %

	10y	5y	3y
Sales	—	21.39%	(1.99%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	22.08%	35.51%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’20	7	1	0	—	8
’19	3	3	1	15	22
’18	2	2	2	4	10
’17	2	2	2	2	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(87)	(77)	—	—	—
’25	(67)	(55)	(64)	(79)	(264)
’24	(53)	(43)	(52)	(61)	(208)
’23	(40)	(32)	(38)	(44)	(154)
’22	(28)	(26)	(34)	(29)	(119)
’21	(11)	(13)	(14)	(21)	(59)
’20	(8)	(8)	(10)	(9)	(36)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(87)	(78)	—	—	—
’25	(67)	(55)	(64)	(80)	(266)
’24	(53)	(43)	(52)	(61)	(208)
’23	(41)	(33)	(38)	(44)	(156)
’22	(29)	(28)	(38)	(31)	(126)
’21	(11)	(13)	(15)	(21)	(60)
’20	(8)	(8)	(2)	(9)	(27)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.53)	(0.52)	—	—	—
’25	(0.52)	(0.53)	(0.50)	(0.61)	(2.16)
’24	(0.62)	(0.59)	(0.64)	(0.61)	(1.94)
’23	(0.54)	(0.59)	(0.64)	(0.63)	(2.42)
’22	(0.68)	(0.71)	(0.50)	(0.56)	(2.39)
’21	(0.34)	(0.43)	(0.48)	(0.61)	(1.87)
’20	(0.80)	(0.96)	(5.07)	(6.06)	(16.17)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	14.38	1.90	1.18	5.83	3.79	3.67	4.28	3.72	Analyst estimates 2026–2028 Powerpack
	High	—	—	70.64	20.32	14.88	13.24	18.07	15.68	12.61	43.73
People
People	Employees	—	53	56	72	15	77	138	164	205	258
	Revenue/emp, $m	0.00	0.16	0.17	0.31	0.52	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	6	8	10	22	8	—	—	—	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	0.00	0.00	—	—	—
	EBT	(18)	(25)	(35)	(32)	(75)	(72)	(140)	(192)	(256)	(329)
	EBT margin, %	(285.19)	(304.93)	(354.76)	(141.49)	(950.43)	0.00	0.00	0.00	0.00	0.00
	Net income	(18)	(25)	(35)	(32)	(75)	(72)	(140)	(192)	(256)	(329)
	Depreciation	1	1	1	1	1	0	(1)	(3)	(5)	1
Per share, $
Per share, $	Revenue	2.49	3.28	1.56	2.95	0.71	0.00	0.00	0.00	0.00	0.00
	Earnings	(7.11)	(10.00)	(5.56)	(4.16)	(16.17)	(1.87)	(2.39)	(2.42)	(1.94)	(2.16)
	Cash flow	(7.32)	(10.14)	(5.22)	(5.45)	(3.24)	(1.52)	(2.02)	(1.93)	(2.00)	(2.05)
	Capex	(1.30)	(0.36)	(0.09)	0.02	0.76	(0.04)	(0.12)	(0.04)	(0.01)	(0.01)
	Free cash flow	(8.62)	(10.50)	(5.31)	(5.43)	(2.48)	(1.56)	(2.14)	(1.96)	(2.01)	(2.06)
	Book value	(9.69)	(19.17)	9.68	4.17	21.18	5.53	4.35	3.24	2.47	4.94
	Shares, m	3	3	6	8	11	39	59	80	104	129
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	P/S	13.52	13.52	11.25	0.98	5.37	—	—	—	—	—
	P/B	0.00	0.00	1.82	0.69	1.01	—	—	—	—	—
	EV/Sales	8.62	8.62	3.18	(0.49)	(4.95)	—	—	—	—	—
	EV/FCF	(2.70)	(2.70)	(0.94)	0.27	4.21	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(19)	(26)	(32)	(42)	(36)	(59)	(119)	(154)	(208)	(264)
	Capex	(3)	(1)	(1)	0	8	(2)	(7)	(3)	(1)	(2)
	Free cash flow	(22)	(27)	(33)	(41)	(27)	(60)	(126)	(156)	(208)	(266)
Balance, $m
Balance, $m	Working capital	61	31	56	27	232	206	238	233	241	846
	Total debt	—	—	—	4	3	1	18	—	—	223
	Net debt	(69)	(41)	(79)	(33)	(239)	(219)	(242)	(266)	(287)	(678)
	Shareholders’ equity	(25)	(49)	60	32	235	214	256	258	256	636
Returns, %
Returns, %	ROA	(48.15)	(41.00)	(51.17)	(47.04)	(119.34)	(29.93)	(52.63)	(62.65)	(79.79)	(51.99)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(688.01)	0.00	0.00	0.00
	ROE	49.46	69.50	(606.74)	(69.21)	(230.42)	(57.23)	(88.01)	(99.26)	(148.99)	(94.98)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2020 · latest quarter Sep 2020

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CGON CG Oncology, Inc.	$5.5B	— (loss-making)	— (loss-making)	+2,125.00% (above 0%: growing)	n/m	−67.60% (below 0%: shrinking)	(239.24%)	(7,467.68%)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
ERAS Erasca, Inc.	$5.2B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%	Compare
CRSP CRISPR Therapeutics AG	$5.0B	— (loss-making)	— (loss-making)	+1,041.37% (above 0%: growing)	n/m	+26.19% (above 0%: growing)	100.00%	(1,151.84%)	Compare
TVTX Travere Therapeutics, Inc.	$5.0B	— (loss-making)	196×	+48.17% (above 0%: growing)	n/m	+604.22% (above 0%: growing)	98.72%	2.33%	Compare
SRRK Scholar Rock Holding Corporation	$5.0B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%	Compare
ORKA Oruka Therapeutics, Inc.	$4.9B	— (loss-making)	—	—	n/m	−43.00% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.0B	—	—	+353.29%	—	+2.11%	41.39%	0.00%

All 614 Biotechnology stocks →

Cogent Biosciences, Inc. (COGT) key facts

Cogent Biosciences, Inc. (COGT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, COGT traded at $29.52, a market capitalization of $5.1 billion.
Return on equity was −95.0% and debt-to-equity 0.42.

Source: company filings (standardised) and stockrow calculations.